PUT/VERTEX PHARMACEUTICALS/400/0.1/17.01.25 | Market Closed - BOERSE MUENCHEN 11:57:08 28/06/2024 pm IST | ||
| 0.73 EUR | +5.80% |
|
| Current month | -47.48% | ||
| 1 month | -46.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.73 | +5.80% |
| 27/24/27 | 0.69 | -2.82% |
| 26/24/26 | 0.71 | -2.74% |
| 25/24/25 | 0.73 | -13.10% |
| 24/24/24 | 0.84 | +2.44% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP4HLN |
| ISIN | DE000GP4HLN1 |
| Date issued | 09/05/2023 |
| Strike | 400 $ |
| Maturity | 17/01/2025 (203 Days) |
| Parity | 10 : 1 |
| Emission price | 6.84 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.65 € |
|---|---|
| Lowest since issue | 0.65 € |
| Spread | 0.2 € |
| Spread % | 21.98% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
